Journal ArticleDOI
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
TLDR
Transdermal rotigotine significantly improved “off” time in subjects with Parkinson disease not optimally controlled with levodopa and was safe and well tolerated, with typical dopaminergic side effects and occasional application site reactions.Abstract:
Background: In patients experiencing motor fluctuations, a major treatment challenge is the reduction of “off” time, particularly upon awakening. Rotigotine (Neupro) is a novel dopaminergic agonist with 24-hour transdermal delivery. Methods: A randomized, double-blind, placebo-controlled trial (PREFER Study) was performed to assess efficacy and safety with two targeted transdermal doses of rotigotine in subjects with advanced Parkinson disease with ≥2.5 hours of daily “off” time. Subjects were randomized to receive placebo patches (n = 120) or rotigotine up to either 8 mg/24 hours (n = 120) or 12 mg/24 hours (n = 111). The primary efficacy measures compared changes from baseline to the end of week 24 in the number of daily hours “off” and responder rates for subjects achieving ≥30% reduction in “off” time. Results: Compared to placebo, there were significant decreases in mean “off” time of 1.8 hours/day for the rotigotine 8 mg/24 hours group and 1.2 hours/day for the 12 mg/24 hours group. For rotigotine 8 and 12 mg/24 hours groups, ≥30% responder rates were 56.6% and 55.1% compared to the 34.5% placebo response. “On” time without dyskinesia after awakening was more than doubled in both rotigotine treatment groups vs placebo. Drug-related adverse effects included typical dopaminergic side effects, which were generally mild/moderate in intensity. Patch application site reactions including erythema and pruritus were mild to moderate and transient in the majority of instances. Conclusions: Transdermal rotigotine significantly improved “off” time in subjects with Parkinson disease not optimally controlled with levodopa and was safe and well tolerated, with typical dopaminergic side effects and occasional application site reactions.read more
Citations
More filters
Journal ArticleDOI
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
Klaus Seppi,Daniel Weintraub,Miguel Coelho,Santiago Perez-Lloret,Susan H. Fox,Regina Katzenschlager,Eva-Maria Hametner,Werner Poewe,Olivier Rascol,Christopher G. Goetz,Cristina Sampaio +10 more
TL;DR: The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non‐motor symptoms and found that most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy.
Journal ArticleDOI
The scientific and clinical basis for the treatment of Parkinson disease (2009)
TL;DR: This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of theDifferent approaches.
Book
Leitlinien für Diagnostik und Therapie in der Neurologie. 5. vollständig überarbeitete Auflage
Hans-Christoph Diener,Christian Weimar,Peter-Dirk Berlit,G Dueschl,Christian E. Elger,Ralf Gold,Werner Hacke,A. Hufschmidt,Heinrich Mattle,U. Meier,W. H. Oertel,Heinz Reichmann,Erich Schmutzhard,C-W Wallesch,Michael Weller +14 more
Journal ArticleDOI
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
Werner Poewe,Olivier Rascol,Niall Quinn,Eduardo Tolosa,Wolfgang H. Oertel,Emilia Martignoni,Markus Rupp,Babak Boroojerdi +7 more
TL;DR: Continuous delivery of rotigotine as transdermal patches could offer similar efficacy to oral pramipexole in patients with fluctuating Parkinson's disease over 6 months of treatment.
Journal ArticleDOI
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
Joaquim J. Ferreira,R. Katzenschlager,B.R. Bloem,Ubaldo Bonuccelli,David J. Burn,Günther Deuschl,Espen Dietrichs,Giovanni Fabbrini,A. Friedman,Petr Kanovsky,Vladimir S. Kostic,Alice Nieuwboer,Per Odin,Werner Poewe,O. Rascol,O. Rascol,Cristina Sampaio,Michael Schüpbach,Michael Schüpbach,Eduard Tolosa,Claudia Trenkwalder,Anthony H.V. Schapira,Alfredo Berardelli,Wolfgang H. Oertel +23 more
TL;DR: To summarize the 2010 EFNS/MDS‐ES evidence‐based treatment recommendations for the management of Parkinson's disease, this summary includes the treatmentRecommendations for early and late PD.
References
More filters
Journal ArticleDOI
Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
TL;DR: Pramipexole improved motor function of patients during "on" and"off" periods, decreased the time spent in "off") periods, reduced the severity of "off"periods, decreased disability and PD severity as assessed by the Unified Parkinson Disease Rating Scale, and permitted a reduction in levodopa dosage.
Journal ArticleDOI
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia.
Robert A. Hauser,Jeffrey Friedlander,Theresa A. Zesiewicz,Charles H. Adler,Lauren Seeberger,Christopher F. O'Brien,Eric Molho,Stewart A. Factor +7 more
TL;DR: It is argued that patients might not be improved if off time is reduced only to the extent that unwanted dyskinesia is increased, so a home diary should include an assessment of dyskine to provide an accurate reflection of clinical status over a period of time.
Journal ArticleDOI
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
Abraham Lieberman,C. W. Olanow,Kapil D. Sethi,Phillip D. Swanson,Cheryl H. Waters,Stanley Fahn,Howard I. Hurtig,Melvin D. Yahr +7 more
TL;DR: Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations and delays the possibility of adverse effect onset.
Journal ArticleDOI
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
TL;DR: It is concluded that pramipexole-treated patients with advanced PD improved significantly more than placebo for both primary end points and in regard to comparison of the Global Clinical Assessment of Efficacy between active treatment groups, there was a trend to significance in favor of pramipingxole.
Journal ArticleDOI
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
Adrian Newman-Tancredi,Didier Cussac,Valérie Audinot,Jean-Paul Nicolas,Frédéric De Ceuninck,Jean-A. Boutin,Millan Mark +6 more
TL;DR: In conclusion, antiparkinson agents display diverse agonist and antagonist properties at multiple subtypes of D2-like receptor and α1/α2-AR, actions, which likely contribute to their contrasting functional profiles.
Related Papers (5)
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER)
Claudia Trenkwalder,Bryan Kies,Monika Rudzińska,Jennifer Fine,Janos Nikl,Krystyna Honczarenko,Peter Dioszeghy,Dennis Hill,Tim J. Anderson,Vilho V. Myllylä,Jan Kassubek,Malcolm Steiger,Marco Zucconi,Eduardo Tolosa,Werner Poewe,Erwin Surmann,John Whitesides,Babak Boroojerdi,Kallol Ray Chaudhuri +18 more
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Robert G. Holloway,Ira Shoulson,K. Kieburtz,Michael P. McDermott,Pierre N. Tariot,Cornelia Kamp,Denni Day,Aileen Shinaman,S. Fahn,Anthony E. Lang,Kenneth Marek,John Seibyl,W. Weiner,M. Welsh,R. Pahwa,S. Coe,L. Barclay,L. Sutherland,K. Hildebrand,J. Hubble,C. Weeks,P. LeWitt,J. Miyasaki,J. Duff,E. Sime,O. Suchowersky,Mark Stacy,M. Kurth,M. Brewer,M. Harrigan,D. S. Russell,B. Fussell,B. Ford,S. Dillon,J. Hammerstad,C. Stone,D. Riley,P. Rainey,David G. Standaert,M. Tennis,F. Wooten,E. Rost-ruffner,S. Factor,D. Brown,Joseph Jankovic,F. Atassi,Roger Kurlan,Irenita Gardiner,M. Panisset,D. Amyot,J. Hall,A. Rajput,Theresa Shirley,Robert L. Rodnitzky,J. Dobson,C. Shults,D. Fontaine,C. Waters,S. Schuman,R. Pfeiffer,Shirley A. Rast,B. Pfeiffer,Alicia Brocht,Cindy Casaceli,Susan Daigneault,Karen Hodgeman,K. Honsinger,C. O'Connell,Arthur Watts +68 more
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Robert G. Holloway,Ira Shoulson,Stanley Fahn,Karl Kieburtz,Anthony E. Lang,Kenneth Marek,Michael P. McDermott,John Seibyl,William J. Weiner,Bruno Musch,Cornelia Kamp,Mickie Welsh,Aileen Shinaman,Rajesh Pahwa,Lynn Barclay,Jean P. Hubble,Peter A. LeWitt,Janis M. Miyasaki,Oksana Suchowersky,Mark Stacy,David S. Russell,Blair Ford,John P. Hammerstad,David E. Riley,David G. Standaert,Frederick Wooten,Stewart A. Factor,Joseph Jankovic,Farah Atassi,Roger Kurlan,Michel Panisset,Ali H. Rajput,Robert L. Rodnitzky,Cliff Shults,Giselle Petsinger,Cheryl Waters,Ronald F. Pfeiffer,Kevin M. Biglan,Leona Borchert,Amy Montgomery,Laura Sutherland,Carolyn Weeks,Maryan DeAngelis,Elspeth Sime,Susan Wood,Carol Pantella,Mary Harrigan,Barbara Fussell,Sandra Dillon,Barbara Alexander-Brown,Pamela Rainey,Marsha Tennis,Elke Rost-Ruffner,Diane Brown,Sharon Evans,Debra Berry,Jean Hall,Theresa Shirley,Judith Dobson,Deborah Fontaine,Brenda Pfeiffer,Alicia Brocht,Susan E. Bennett,Susan Daigneault,Karen Hodgeman,Carolynn O'Connell,Tori Ross,Karen Richard,Arthur Watts +68 more